The biological features of PanIN initiated from oncogenic Kras mutation in genetically engineered mouse models

Cancer Letters

Volumn 339, Issue 1, 2013, Pages 135-143

  Shen, Ruizhe ^a   Wang, Qi ^a   Cheng, Shidan ^a   Liu, Tingting ^a   Jiang, He ^a   Zhu, Jiaxing ^a   Wu, Yunlin ^a   Wang, Lifu ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Kras; Pancreatic cancer; PanIN; PPP2R2A; Tp53

Indexed keywords

BETA CATENIN; CRE RECOMBINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN P53; SMAD4 PROTEIN; TRANSCRIPTION FACTOR PDX 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BETA CATENIN GENE; CANCER CELL CULTURE; CANCER MORPHOLOGY; CANCER SURVIVAL; CARCINOGENESIS; CELL ISOLATION; CELL MIGRATION; CONTROLLED STUDY; CRE GENE; EGFR GENE; GENE; GENE EXPRESSION; GENE MUTATION; HER 2 GENE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LSL GENE; MALIGNANT TRANSFORMATION; MOLECULAR BIOLOGY; MOUSE; NEU GENE; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOGENE K RAS; P MAPK GENE; PANCREAS ADENOMA; PANCREAS SURGERY; PANCREAS TUMOR; PDX 1 GENE; PPP2R2A GENE; PRIORITY JOURNAL; SMAD4 GENE; SYMPTOMATOLOGY; TP53 GENE; TUMOR INVASION;

KRAS; PANCREATIC CANCER; PANCREATIC DUCTAL ADENOCARCINOMA; PANCREATIC INTRAEPITHELIAL NEOPLASIA; PANIN; PDAC; PPP2R2A; PROTEIN PHOSPHATASE 2, REGULATORY SUBUNIT B, ALPHA; TP53;

ANIMALS; CARCINOMA IN SITU; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, RAS; HUMANS; MICE; MICE, TRANSGENIC; MUTATION; PANCREATIC NEOPLASMS; PROTEIN PHOSPHATASE 2; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2;

EID: 84883450332     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.07.010     Document Type: Article

References (25)

1. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. CA Cancer J. Clin. 2010, 60(2010):277-300.
2. Iacobuzio-Donahue C.A., Velculescu V.E., Wolfgang C.L., Hruban R.H. Genetic basis of pancreas cancer development and progression: insights from whole-exome and whole-genome sequencing. Clin. Cancer Res. 2012, 18:4257-4265.
3. Almoguera C., Shibata D., Forrester K., Martin J., Arnheim N., Perucho M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 1988, 53:549-554.
4. Caldas C., Hahn S.A., da Costa L.T., Redston M.S., Schutte M., Seymour A.B., Weinstein C.L., Hruban R.H., Yeo C.J., Kern S.E. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat. Genet. 1994, 8:27-32.
5. Redston M.S., Caldas C., Seymour A.B., Hruban R.H., da Costa L., Yeo C.J., Kern S.E. P53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. Cancer Res. 1994, 54:3025-3033.
6. Hahn S.A., Schutte M., Hoque A.T., Moskaluk C.A., da Costa L.T., Rozenblum E., Weinstein C.L., Fischer A., Yeo C.J., Hruban R.H., Kern S.E. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 1996, 271:350-353.
7. Hezel A.F., Kimmelman A.C., Stanger B.Z., Bardeesy N., Depinho R.A. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev. 2006, 20:1218-1249.
8. Morris J.P.t., Wang S.C., Hebrok M. KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma. Nat. Rev. Cancer 2010, 10:683-695.
9. Hruban R.H., Rustgi A.K., Brentnall T.A., Tempero M.A., Wright C.V., Tuveson D.A. Pancreatic cancer in mice and man: the Penn Workshop. Cancer Res. 2004, 66(2006):14-17.
10. Hruban R.H., Adsay N.V., Albores-Saavedra J., Anver M.R., Biankin A.V., Boivin G.P., Furth E.E., Furukawa T., Klein A., Klimstra D.S., Kloppel G., Lauwers G.Y., Longnecker D.S., Luttges J., Maitra A., Offerhaus G.J., Perez-Gallego L., Redston M., Tuveson D.A. Pathology of genetically engineered mouse models of pancreatic exocrine cancer: consensus report and recommendations. Cancer Res. 2006, 66:95-106.
11. Hingorani S.R., Petricoin E.F., Maitra A., Rajapakse V., King C., Jacobetz M.A., Ross S., Conrads T.P., Veenstra T.D., Hitt B.A., Kawaguchi Y., Johann D., Liotta L.A., Crawford H.C., Putt M.E., Jacks T., Wright C.V., Hruban R.H., Lowy A.M., Tuveson D.A. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 2003, 4:437-450.
12. Hingorani S.R., Wang L., Multani A.S., Combs C., Deramaudt T.B., Hruban R.H., Rustgi A.K., Chang S., Tuveson D.A. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 2005, 7:469-483.
13. Olive K.P., Jacobetz M.A., Davidson C.J., Gopinathan A., McIntyre D., Honess D., Madhu B., Goldgraben M.A., Caldwell M.E., Allard D., Frese K.K., Denicola G., Feig C., Combs C., Winter S.P., Ireland-Zecchini H., Reichelt S., Howat W.J., Chang A., Dhara M., Wang L., Ruckert F., Grutzmann R., Pilarsky C., Izeradjene K., Hingorani S.R., Huang P., Davies S.E., Plunkett W., Egorin M., Hruban R.H., Whitebread N., McGovern K., Adams J., Iacobuzio-Donahue C., Griffiths J., Tuveson D.A. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009, 324:1457-1461.
14. Perez-Mancera P.A., Guerra C., Barbacid M., Tuveson D.A. What we have learned about pancreatic cancer from mouse models. Gastroenterology 2012, 142:1079-1092.
15. Tuveson D., Hanahan D. Translational medicine: cancer lessons from mice to humans. Nature 2011, 471:316-317.
16. Wang Q., Liu H., Liu T., Shu S., Jiang H., Cheng S., Yuan Y., Yang W., Wang L. BRCA2 dysfunction promotes malignant transformation of pancreatic intraepithelial neoplasia. Anticancer Agents Med. Chem. 2013, 13:261-269.
17. Wang L.F., Hingorani S.R., Tuveson D.A. Detecting and diagnosing ampullary neoplasms. Cancer Biol. Ther. 2004, 3:657-659.
18. Vogelstein B., Fearon E.R., Hamilton S.R., Kern S.E., Preisinger A.C., Leppert M., Nakamura Y., White R., Smits A.M., Bos J.L. Genetic alterations during colorectal-tumor development. N. Engl. J. Med. 1988, 319:525-532.
19. Hruban R.H., Adsay N.V., Albores-Saavedra J., Compton C., Garrett E.S., Goodman S.N., Kern S.E., Klimstra D.S., Kloppel G., Longnecker D.S., Luttges J., Offerhaus G.J. Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions. Am. J. Surg. Pathol. 2001, 25:579-586.
20. Hruban R.H., Takaori K., Klimstra D.S., Adsay N.V., Albores-Saavedra J., Biankin A.V., Biankin S.A., Compton C., Fukushima N., Furukawa T., Goggins M., Kato Y., Kloppel G., Longnecker D.S., Luttges J., Maitra A., Offerhaus G.J., Shimizu M., Yonezawa S. An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Am. J. Surg. Pathol. 2004, 28:977-987.
21. Mebratu Y., Tesfaigzi Y. How ERK1/2 activation controls cell proliferation and cell death: is subcellular localization the answer?. Cell Cycle 2009, 8:1168-1175.
22. Hingorani S.R., Tuveson D.A. Ras redux: rethinking how and where Ras acts. Curr. Opin. Genet. Dev. 2003, 13:6-13.
23. Tuveson D.A., Shaw A.T., Willis N.A., Silver D.P., Jackson E.L., Chang S., Mercer K.L., Grochow R., Hock H., Crowley D., Hingorani S.R., Zaks T., King C., Jacobetz M.A., Wang L., Bronson R.T., Orkin S.H., DePinho R.A., Jacks T. Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell 2004, 5:375-387.
24. Iatropoulos M.J., Williams G.M. Proliferation markers. Exp. Toxicol. Pathol. 1996, 48:175-181.
25. kuo Y.C., Huang K.Y., Yang C.H., Yang Y.S., Lee W.Y., Chiang C.W. Regulation of phosphorylation of Thr-308 of Akt, cell proliferation, and survival by the B55 alpha regulatory subunit targeting of the protein phosphatase 2A holoenzyme to Akt. J. Biol. Chem. 2008, 283:1882-1892.